Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/7/2009

ements of Operations (in thousands) Three months Ended March 31, 2009 2008 (unaudited) (unaudited) Operating expenses Research and development $ 1,694 $ 874 General and administrative 782 573 ------------------------- Total operating expenses 2,476 1,447 Other income (expense) 57 4 Loss for the period before taxes 2,419 1,443 Income tax expense (recovery) (10) 214 Net loss 2,409 1,657 Redeemable convertible preferred share accretion - 776 ------------------------- Loss attributable to common shareholders $ 2,409 $ 2,433 Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2009 2008 (unaudited) Assets: Cash, cash equivalents and short term investments $ 9,393 $ 12,419 Amounts and investment tax credit receivable 515 1,243 Prepaid and other current assets 631 587 Property, equipment and other assets 558 541 ------------------------- Tot
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
2. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
3. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
4. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
5. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
6. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
7. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
8. OncoGenex Reports Third Quarter Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... of Wisconsin-Madison is one of 10 institutions to receive ... Departments of Energy and Agriculture . ... and Agriculture Secretary Mike Johanns, include a $333,000 award ... university in the nation, according to statistics released by ...
... title of this article is deliberately misleading. It feeds ... by a bunch of generational tribes engaged in rivalries ... differences, misunderstandings and tensions among workers born in different ... conflict is overblown in my view. , ,Recently, I ...
... Colorado to Wisconsin. Theyre similarly sized states, all removed from ... being a high-tech haven. , ,But the comparisons end when ... industries. There, Wisconsin is a dismal third, and it helps ... keep up with the Joneses. , ,While it is a ...
Cached Biology Technology:UW-Madison gets $333,000 for biofuels research 2Geezers, grungers, gen-Xers and geeks - a look at workplace generational conflict 2Geezers, grungers, gen-Xers and geeks - a look at workplace generational conflict 3Geezers, grungers, gen-Xers and geeks - a look at workplace generational conflict 4Wisconsin's failure to attract federal defense dollars crimps tech economy 2Wisconsin's failure to attract federal defense dollars crimps tech economy 3
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... Over the past decade various pieces of the puzzle ... Now, in Cell an international team reports ... Their results show that interaction with a linear ubiquitin ... Their findings may also contribute towards structure-based drug design ...
... MADISON The adage that dead men tell no tales ... science is taking interrogation of the dead to new heights. ... into the earliest European visitors to the New World, a ... the chemical details of life history from the teeth of ...
... Alcohol-related deaths in England and Wales are twice as high ... rest of the population, a study has shown. Research, ... National Statistics, also found that men born in India ... of alcohol-related death as Scottish- and Irish-born people. The ...
Cached Biology News:A paradigm shift in immune response regulation 2A paradigm shift in immune response regulation 3Teeth of Columbus' crew flesh out tale of new world discovery 2Teeth of Columbus' crew flesh out tale of new world discovery 3Scots and Irish at greater risk of drink-related death, study shows 2
HSV 1 IgG...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
Request Info...
Biology Products: